Results 41 to 50 of about 15,170 (273)
Antibody–drug conjugates: Recent advances in linker chemistry
Acta Pharmaceutica Sinica B, 2021 Antibody–drug conjugates (ADCs) are gradually revolutionizing clinical cancer therapy. The antibody–drug conjugate linker molecule determines both the efficacy and the adverse effects, and so has a major influence on the fate of ADCs.
Zheng Su +7 more
doaj +1 more source
The Study of mpValCitGlyPro Linker for Alcohol Payload Release [PDF]
, 2021 Antibody-drug-conjugates (ADCs) are a class of drugs that deliver potent payloads to specific cells or tissues via cell-specific uptake. ADCs are composed of an antibody that is specific to the intended target which is tethered to a payload by a ...
Howe, Justin +4 more
core +1 more source
Antibody–Drug Conjugates for the Treatment of Breast Cancer [PDF]
, 2021 Metastatic breast cancer (BC) is currently an incurable disease. Besides endocrine therapy and targeted agents, chemotherapy is often used in the treatment of this disease.
Eleonora Nicolò +4 more
core +4 more sources
OncoImmunology, 2019 Oncology treatment has been revolutionized by the introduction of immune checkpoint inhibitor drugs, which enable 20–40% of patients to generate anti-tumor immune responses.
Maxine Bauzon +5 more
doaj +1 more source
Journal of Hematology & Oncology, 2023 Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios.
Alfonso López de Sá +10 more
doaj +1 more source
Payload of T-DM1 binds to cell surface cytoskeleton-associated protein 5 to mediate cytotoxicity of hepatocytes [PDF]
Oncotarget, 2018 Off-target toxicity is a major cause of dose-limiting toxicity for antibody-drug conjugates (ADCs), mechanisms of which remain poorly understood. Here, we demonstrate that cytoskeleton-associated protein 5 (CKAP5) serves as a cell surface target for T-DM1 and that binding of T-DM1 to CKAP5 is mediated by payload (DM1).
Endo, Yukinori +6 more
openaire +2 more sources
Antibody–drug conjugate: a newly developed biological missile for tumor treatment
Frontiers in OncologyAntibody–drug conjugates (ADCs) represent one of the most advanced drug configurations under current research, primarily composed of a monoclonal antibody (mAb), a highly potent cytotoxic payload, and a linker that connects the drug to the antibody.
Zhuoran Tang, Yanchun Xie, Yanping Zeng
doaj +1 more source
DataSheet1_Click Chemistry and Multicomponent Reaction for Linker Diversification of Zinc Dipicolylamine-Based Drug Conjugates.PDF [PDF]
, 2022 An efficient Ugi multicomponent reaction with strain promoted azide-alkyne cycloaddition protocol has been utilized in concert or independently to prepare a small family of bioactive zinc(II) dipicolylamine (ZnDPA)-based SN-38 conjugates. With sequential
Lun Kelvin Tsou (4182223) +7 more
core +1 more source
Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential [PDF]
, 2022 Antibody-drug conjugates (ADCs) constitute a relatively new group of anticancer agents, whose first appearance took place about two decades ago, but a renewed interest occurred in recent years, following the success of anti-cancer immunotherapy with ...
Lacal, PM, Ceci, C, Graziani, G
core +1 more source
Advanced Functional Materials, EarlyView.An intrinsic photoactive star‐shaped zinc phtalocyanine‐poly(L‐glutamic acid) (ZnPc‐PGA) nanoplatform for multimodal glioblastoma (GBM) therapy and brain‐targeted elivery. A ZnPc‐PGA‐based multifunctional theranostic nanocarrier platform enables image‐guided, multimodal GBM therapy. ZnPc‐PGA nanocarriers support the integration of fluorescence imaging,
Amina Benaicha‐Fernández +14 more
wiley +1 more source